The report "Parkinsons Disease
Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists,
MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies),
Patient Care Setting (Hospitals, Clinics) - Global Forecast",
Parkinson’s Disease DrugsMarket Overview, Demand, New
Opportunities & SWOT Analysis
The Parkinson’s Disease Drugs market
is being driven by the growth in aging population and the associated increase
in the prevalence of Parkinsons disease and government funding for research.
Download PDF Brochure: @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47265247
This report aims to provide insights into
the global Parkinson’s disease treatment market. It provides valuable
information on the market classification by drug class, distribution channels,
and patient care setting. Details on regional markets for these segments have
also been presented in this report. In addition, leading players in the market
are profiled to understand the strategies undertaken by them to be competitive
in this market.
The Parkinsons disease treatment market is
expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a
CAGR of 6.1%.
By drug class, the carbidopa/levodopa
segment is estimated to dominate the market in 2017
On the basis of drug class, the Parkinsons
disease therapeutic drugs market is segmented into carbidopa/levodopa, dopamine
receptor agonists, MAO inhibitors, COMT inhibitors, anticholinergics, and other
drugs. In 2017, the carbidopa/levodopa segment is expected to account for the
largest share of the market. Carbidopa/levodopa drugs are more potent than most
other drug classes are hence widely used in the treatment of Parkinson’s
disease.
By distribution channel, the hospital
pharmacies segment is estimated to hold the largest share of the market in 2017
By distribution channel, the Parkinsons
disease therapeutic drugs market has been segmented into hospital pharmacies,
retailer pharmacies, and online pharmacies. In 2017, the hospital pharmacies
segment is expected to account for the largest share of the market. The large
share of this segment can primarily be attributed to the availability of a wide
range of drugs in these facilities and the increasing number of patient visits
to hospitals.
Browse complete Report along with TOC @ https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html
Hospitals to dominate the Parkinsons
disease treatment market during the forecast period
The Parkinsons disease treatment market is
classified by patient care settings into hospitals and clinics. In 2017, the
hospital segment is expected to command the largest share and is estimated to
grow at the fastest rate as compared to clinics segment. This market is mainly
driven by robust healthcare services provided in hospitals and the presence of
skilled neurologists in the hospitals.
Asia to offer lucrative growth
opportunities
By region, the global Parkinsons disease
treatment market is segmented into North America, Europe, Asia, and the Rest of
the World (RoW). While Europe is expected to hold the largest share of the
market in 2017, Asia is expected to grow at the highest CAGR during the
forecast period. Increasing number of players in the region and the rising
aging population are some major factors driving the high growth of this
regional segment.
Some of the major players operating in the
Parkinsons disease treatment market include Teva (Israel), Novartis AG
(Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim
(Germany), Impax Laboratories (US),
Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium),
Valeant Pharmaceuticals (Canada), and Acadia (US).
Tevais one
of the key players in the Parkinson’s disease treatment market. The company
focuses on organic and inorganic strategies to strengthen its position in the
Parkinson’s disease treatment market. For instance, in 2015, the company
entered into an agreement with Takeda pharmaceutical company to commercialize
rasagiline tablets in the Japan.
Moreover, the company received FDA approval for AZILECT drug to treat
all stages of the Parkinson’s disease
Access Sample Copy of the Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=47265247
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B
research on 30,000 high growth niche opportunities/threats which will impact
70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers
worldwide including 80% of global Fortune 1000 companies as clients. Almost
75,000 top officers across eight industries worldwide approach
MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at
MarketsandMarkets™ are tracking global high growth markets following the
"Growth Engagement Model – GEM". The GEM aims at proactive
collaboration with the clients to identify new opportunities, identify most
important customers, write "Attack, avoid and defend" strategies,
identify sources of incremental revenues for both the company and its
competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants
(Positioning top players across leaders, emerging companies, innovators,
strategic players) annually in high growth emerging segments.
MarketsandMarkets™ is determined to benefit more than 10,000 companies this
year for their revenue planning and help them take their
innovations/disruptions early to the market by providing them research ahead of
the curve.
MarketsandMarkets’s flagship competitive
intelligence and market research platform, "RT" connects over 200,000
markets and entire value chains for deeper understanding of the unmet insights
along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
The Wall